We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Showcases Latest Developments for Diagnostics Market at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: Acusera 24•7 is a live, cloud based interlaboratory data management and peer group reporting software (Photo courtesy of Randox)
Image: Acusera 24•7 is a live, cloud based interlaboratory data management and peer group reporting software (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is showcasing its latest developments for the diagnostics market at Medlab Middle East 2023 taking place live, in-person from 6-9 February 2023, in Dubai.

At the 22nd edition of Medlab Middle East Congress, Randox is highlighting its RX series of clinical chemistry analyzers for high quality semi-automated and fully automated testing, including RX daytona+, RX Monaco, RX imola, RX Modena, and RX misano. The RX series combines robust hardware and intuitive software with the world leading RX series test menu, including routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants and diabetes testing. Renowned for quality and reliability, the RX series has one of the most extensive dedicated clinical chemistry test menus on the market guaranteeing real cost savings through consolidation of routine and specialized tests onto a single platform. This extensive dedicated test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results. With placements in over 120 countries worldwide, the RX series continues to revolutionize a variety of laboratory types including clinical laboratories and hospital laboratories.

At this year’s Medlab Middle East, Randox is also showcasing the Vivalytic platform, a universal, fully automated all in one solution for molecular diagnostics, the VeraSTAT portable point of care reader based on cathodic electro chemiluminescence technology, and the Discovery molecular & immunoassay diagnostic analyzer. Also on display at the show is the fully automated Evidence MultiSTAT immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood.

In addition, Randox is presenting its extensive range of third party diagnostic reagents which produce accurate and precise results, alongside Acusera true third party quality controls that offer complete test menu consolidation for laboratory Internal Quality Control. Alongside, Randox is demonstrating Acusera 24.7, an Interlaboratory data management and peer group reporting package complementing the Acusera range of true third-party controls. Designed to help laboratories efficiently and effectively manage their daily QC activities, Acusera 24.7 offers several benefits to laboratories.

Related Links:
Randox Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more